Announcement

Collapse
No announcement yet.

Doctors: Patents Keep HIV Drugs Too Pricy To Use

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Doctors: Patents Keep HIV Drugs Too Pricy To Use

    DOCTORS: PATENTS KEEP HIV DRUGS TOO PRICY TO USE

    The Associated Press
    July 2, 2013 Tuesday 08:18 AM GMT

    Doctors Without Borders warned Tuesday that rising intellectual
    property rights are blocking the generic production of newer drugs to
    treat HIV and are keeping them out of reach for developing countries.

    The medical aid group said at an international AIDS meeting here
    that prices of older drugs long used to treat patients have fallen
    sharply as India and other countries make generics. But newer drugs
    that are more effective against the AIDS virus are too expensive,
    costing up to 15 times more.

    "It's good news that the price of key HIV drugs continues to fall
    as more generic companies compete for the market, but the newer
    medicines are still priced far too high," said Jennifer Cohn, medical
    director for Doctors Without Borders' access campaign. "We need the
    newer treatments for people that have exhausted all other options,
    but patents keep them priced beyond reach."

    Patients can be treated with a combination of three or four older
    drugs, but those who develop resistance to them need the expensive
    newer medicines.

    According to Doctors Without Borders, the governments of Thailand and
    Jamaica pay $4,760 and $6,570, respectively, a year per patient for
    the new drug darunavir alone. Paraguay pays $7,782 for etravirine,
    while Armenia pays $13,213 for raltegravir. In comparison, a cocktail
    of older generic drugs costs as little as $139 per person a year.

    Doctors Without Borders urged the United States and 11 other countries
    negotiating a Trans-Pacific Partnership not to sign the free-trade
    pact. It warned that the pact will increase intellectual property
    rights across Asia and the Americas, expanding monopoly protection
    for medicines and threatening cheap access to drugs.

    It said the World Health Organization's new guidelines, which
    recommend earlier treatment for adults, means that an additional
    9 million people in developing countries will now be eligible for
    treatment. At the moment, only about 60 percent of those who need
    the drugs are getting them.

    "Scaling up HIV treatment and sustaining people on treatment for
    life will depend on bringing the price of newer drugs down," said
    Arax Bozadijan, an HIV pharmacist for Doctors Without Borders.

    The Trans-Pacific pact countries account for nearly 40 percent of
    global GDP and about a third of world trade, and any agreement could
    significantly impact prices. President Barack Obama's administration
    has said it hopes to wrap up talks by the end of the year.

Working...
X